Sertoli cell tumor

Inhibin A is also a sensitive marker of Sertoli cell differentiation (>90% positive). Sertoli cell tumor including its large cell calcifying variant stains variably positive with antibodies to vimentin, cytokeratin, S-100, synaptophy-sin, chromogranin, and neuron-specific enolase. Cytokeratin immunoreactivity in Sertoli cell tumors is usually stronger than that seen in Leydig cell tumors. Immunoreactivity for FLAP is not seen in Sertoli cell tumors. 

Tubular seminoma, which often mimics Sertoli cell tumor architecturally, can be separated from Sertoli cell tumor by its FLAP immunoreactivity and lack of staining for inhibin and cytokeratins. Like Leydig cell tumors, CD99 can be a useful adjunct in identifying Sertoli cell tumors (Table I6.22). > 403,509,5ii-5i7... 

Gilcrease MZ, Delgado R, Albores-Saavedra J. Testicular Sertoli cell tumor with a heterologous sarcomatous component immu-nohistochemical assessment of Sertoli cell differentiation. Arch... 

Young RH, Koelliker DD, Scully RE. Sertoli cell tumors of the testis, not otherwise specified a clinicopathologic analysis of 60 cases. Am J Surg Pathol. 1998 22 709. 

Sertoli cell tumors are rare benign neoplasms in which Sertoli cells line tubules or grow in trabeculae. 

They lack the primitive stroma and Leydig cells that are present in Sertoli-Leydig cell tumors. Oxyphilic and lipid-rich variants have been described, and Sertoli cell tumors can contain areas of diffuse growth. Immu-nohistochemistry can help to confirm the diagnosis and to differentiate a Sertoli cell tumor from such differential diagnostic considerations as Sertoliform endometrioid... 

SOX9 is a transcription factor involved in Sertoli cell differentiation in the testis and is variably expressed in a variety of ovarian tumors (44% of Sertoli cell tumors. 

Zhao C, Bratthauer GL, Barner R, et al. Immunohistochemical analysis of sox9 in ovarian Sertoli cell tumors and other tumors in the differential diagnosis. Int J Gynecol Pathol. 2007 26 1-9. 

---